Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy-Reference-Cited by-同舟云学术

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Published:2020-03-11 Issue:534 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Mayoux Maud¹^ORCID,Roller Andreas²,Pulko Vesna¹,Sammicheli Stefano¹^ORCID,Chen Stanford¹,Sum Eva¹^ORCID,Jost Christian¹^ORCID,Fransen Marieke F.³^ORCID,Buser Regula B.¹,Kowanetz Marcin⁴,Rommel Karolin¹,Matos Ines¹^ORCID,Colombetti Sara¹,Belousov Anton⁵^ORCID,Karanikas Vaios¹,Ossendorp Ferry³,Hegde Priti S.⁴,Chen Daniel S.⁶^ORCID,Umana Pablo¹^ORCID,Perro Mario¹^ORCID,Klein Christian¹^ORCID,Xu Wei¹^ORCID

Affiliation:

1. Cancer Immunotherapy Discovery, Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren 8952, Switzerland.

2. Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology, Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel 4070, Switzerland.

3. Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden 2333, Netherlands.

4. Oncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

5. Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics, Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg 82377, Germany.

6. Product Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

Abstract

DCs are critical cellular targets of PD-L1 blockade in cancer treatment.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference29 articles.

1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

2. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

3. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

5. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Cited by 269 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights into immune cells modulation of tumor resistance;Critical Reviews in Oncology/Hematology;2024-10

2. β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer;BMC Immunology;2024-09-14

3. Immune checkpoint reprogramming via sequential nucleic acid delivery strategy optimizes systemic immune responses for gastrointestinal cancer immunotherapy;Cancer Letters;2024-09

4. Remodeling the hepatic immune microenvironment and demolishing T cell traps to enhance immunotherapy efficacy in liver metastasis;Journal of Controlled Release;2024-09

5. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09